SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.

Cerebrospinal fluid amyloid-beta 1-42 (Aβ1-42) and phosphorylated Tau at position 181 (pTau181) are biomarkers of Alzheimer's disease (AD). We performed an analysis and meta-analysis of genome-wide association study data on Aβ1-42 and pTau181 in AD dementia patients followed by independent replication. An association was found between Aβ1-42 level and a single-nucleotide polymorphism in SUCLG2 (rs62256378) (P = 2.5×10(-12)). An interaction between APOE genotype and rs62256378 was detected (P = 9.5 × 10(-5)), with the strongest effect being observed in APOE-ε4 noncarriers. Clinically, rs62256378 was associated with rate of cognitive decline in AD dementia patients (P = 3.1 × 10(-3)). Functional microglia experiments showed that SUCLG2 was involved in clearance of Aβ1-42.

HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy

Background: Although combination antiretroviral therapy (cART) dramatically reduces rates of AIDS and death, a minority of patients experience clinical disease progression during treatment. <p>Objective: To investigate whether detection of CXCR4(X4)-specific strains or quantification of X4-specific HIV-1 load predict clinical outcome. Methods: From the Swiss HIV Cohort Study, 96 participants who initiated cART yet subsequently progressed to AIDS or death were compared with 84 contemporaneous, treated nonprogressors. A sensitive heteroduplex tracking assay was developed to quantify plasma X4 and CCR5 variants and resolve HIV-1 load into coreceptor-specific components. Measurements were analyzed as cofactors of progression in multivariable Cox models adjusted for concurrent CD4 cell count and total viral load, applying inverse probability weights to adjust for sampling bias. Results: Patients with X4 variants at baseline displayed reduced CD4 cell responses compared with those without X4 strains (40 versus 82 cells/mu l; P= 0.012). The adjusted multivariable hazard ratio (HR) for clinical progression was 4.8 [95% confidence interval (Cl) 2.3-10.0] for those demonstrating X4 strains at baseline. The X4-specific HIV-1 load was a similarly independent predictor, with HR values of 3.7(95%Cl, 1.2-11.3) and 5.9 (95% Cl, 2.2-15.0) for baseline loads of 2.2-4.3 and > 4.3 log(10)copies/ml, respectively, compared with < 2.2 log(10)copies/ml. Conclusions: HIV-1 coreceptor usage and X4-specific viral loads strongly predicted disease progression during cART, independent of and in addition to CD4 cell count or total viral load. Detection and quantification of X4 strains promise to be clinically useful biomarkers to guide patient management and study HIV-1 pathogenesis.

Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach.

BACKGROUND: HIV-1 RNA viral load is a key parameter for reliable treatment monitoring of HIV-1 infection. Accurate HIV-1 RNA quantitation can be impaired by primer and probe sequence polymorphisms as a result of tremendous genetic diversity and ongoing evolution of HIV-1. A novel dual HIV-1 target amplification approach was realized in the quantitative COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 (HIV-1 TaqMan test v2.0) to cope with the high genetic diversity of the virus. OBJECTIVES AND STUDY DESIGN: The performance of the new assay was evaluated for sensitivity, dynamic range, precision, subtype inclusivity, diagnostic and analytical specificity, interfering substances, and correlation with the COBAS AmpliPrep/COBAS TaqMan HIV-1 (HIV-1 TaqMan test v1.0) predecessor test in patients specimens. RESULTS: The new assay demonstrated a sensitivity of 20 copies/mL, a linear measuring range of 20-10,000,000 copies/mL, with a lower limit of quantitation of 20 copies/mL. HIV-1 Group M subtypes and HIV-1 Group O were quantified within +/-0.3 log(10) of the assigned titers. Specificity was 100% in 660 tested specimens, no cross reactivity was found for 15 pathogens nor any interference for endogenous substances or 29 drugs. Good comparability with the predecessor assay was demonstrated in 82 positive patient samples. In selected clinical samples 35/66 specimens were found underquantitated in the predecessor assay; all were quantitated correctly in the new assay. CONCLUSIONS: The dual-target approach for the HIV-1 TaqMan test v2.0 enables superior HIV-1 Group M subtype coverage including HIV-1 Group O detection. Correct quantitation of specimens underquantitated in the HIV-1 TaqMan test v1.0 test was demonstrated.

Decreased Probability of Initial Pain Cessation in Classic Trigeminal Neuralgia Treated With Gamma Knife Surgery in Case of Previous Microvascular Decompression: A Prospective Series of 45 Patients With >1 Year of Follow-up.

BACKGROUND: Microvascular decompression (MVD) is the reference technique for pharmacoresistant trigeminal neuralgia (TN). OBJECTIVE: To establish whether the safety and efficacy of Gamma Knife surgery for recurrent TN are influenced by prior MVD. METHODS: Between July 1992 and November 2010, 54 of 737 patients (45 of 497 with >1 year of follow-up) had a history of MVD (approximately half also with previous ablative procedure) and were operated on with Gamma Knife surgery for TN in the Timone University Hospital. A single 4-mm isocenter was positioned in the cisternal portion of the trigeminal nerve at a median distance of 7.6 mm (range, 3.9-11.9 mm) anterior to the emergence of the nerve. A median maximum dose of 85 Gy (range, 70-90 Gy) was delivered. RESULTS: The median follow-up time was 39.5 months (range, 14.1-144.6 months). Thirty-five patients (77.8%) were initially pain free in a median time of 14 days (range, 0-180 days), much lower compared with our global population of classic TN (P = .01). Their actuarial probabilities of remaining pain-free without medication at 3, 5, 7, and 10 years were 66.5%, 59.1%, 59.1%, and 44.3%. The hypoesthesia actuarial rate at 1 year was 9.1% and remained stable until 12 years (median, 8 months). CONCLUSION: Patients with previous MVD showed a significantly lower probability of initial pain cessation compared with our global population with classic TN (P = .01). The toxicity was low (only 9.1% hypoesthesia); furthermore, no patient reported bothersome hypoesthesia. However, the probability of maintaining pain relief without medication was 44.3% at 10 years, similar to our global series of classic TN (P = .85). ABBREVIATIONS: BNI, Barrow Neurological InstituteCI, confidence intervalCTN, classic trigeminal neuralgiaGKS, Gamma Knife surgeryHR, hazard ratioMVD, microvascular decompressionTN, trigeminal neuralgia.

Comparação de métodos convencional e alternativo para determinação de sódio, potássio e fósforo em extratos de solos obtidos com solução de mehlich-1

Foram comparadas as concentrações de Na, K e P em extratos de solos, obtidas por um método de extração convencional, no qual é utilizada uma razão solo:extrator (Mehlich-1) de 1:10, com aquelas encontradas utilizando uma razão solo:extrator (Mehlich-1) de 1:5. Também, foram comparados os resultados obtidos por técnicas de quantificação convencionais, nas quais Na e K são quantificados por fotometria de chama e P por espectrofotometria de absorção molecular, com aqueles encontrados por espectrometria de emissão óptica com plasma indutivamente acoplado (ICP OES). Foram analisadas 15 amostras de solo brasileiro. No estudo de repetibilidade aplicado a todos os resultados, os maiores CVs foram encontrados para P e Na, principalmente quando as concentrações dos analitos foram menores (< 9 mg dm-3 para P e < 10 mg dm-3 para Na). Esse fato foi devido provavelmente à heterogeneidade dos extratos, que continham partículas coloidais. Filtração ou centrifugação em vez de decantação dos extratos provavelmente resultaria em menores CVs. No estudo de reprodutibilidade, realizado para três amostras, foram obtidos resultados não reprodutíveis somente para K em uma amostra. Todos os resultados obtidos por ICP OES foram semelhantes aos obtidos por espectrofotometria de absorção molecular UV-Vis. e fotometria de chama, indicando que a primeira técnica foi adequada para determinação de Na, K e P nos extratos de solos tropicais obtidos com solução de Mehlich-1. Os resultados de Na, K e P obtidos com razão solo:extrator de 1:5 foram estatisticamente diferentes daqueles em que se utilizou razão solo:extrator de 1:10. A maioria dos resultados obtidos com razão solo:extrator de 1:5 foi menor que os obtidos com razão solo:extrator 1:10, sobretudo nas amostras com concentrações de analitos mais elevadas. Portanto, para estudos comparativos envolvendo macronutrientes, deve-se utilizar o método convencional com razão solo:extrator de 1:10.

Comparação de métodos convencional e alternativo para determinar Cu, Fe, Mn e Zn em extratos de solos obtidos com solução de mehlich-1

Nos laboratórios brasileiros, a determinação de micronutrientes para estudos de fertilidade de solos é realizada por extração com solução de Mehlich-1 (M-1), utilizando-se uma razão solo: extrator de 1:5 m/v e posterior quantificação por espectrometria de absorção atômica (AAS). No entanto, muitos laboratórios também empregam razão solo:extrator M-1 de 1:10 m/v para determinar macronutrientes e, ou, quantificar por espectrometria de emissão óptica com plasma indutivamente acoplado (ICP OES), em substituição ao AAS. Como estudos comparativos entre as concentrações de micronutrientes obtidos por esses métodos alternativos são escassos, o objetivo deste trabalho foi investigar se essas diferentes condições experimentais gerariam diferentes resultados. Os resultados foram estatisticamente tratados e revelaram que as concentrações de Fe e Mn, utilizando-se ambas as razões de solo:extrator M-1 (1:5 e 1:10 m/v) e de Zn, na razão solo:extrator M-1 de 1:10 m/v, foram estatisticamente iguais, enquanto as concentrações de Cu em ambas as razões solo:extrator M-1 e de Zn na razão solo:extrator de 1:5 m/v foram diferentes, quando as duas técnicas de quantificação (ICP OES e AAS) foram comparadas. Também, todas as concentrações de Cu, Fe, Mn e Zn obtidas utilizando razão solo:extrator M-1 de 1:5 m/v foram diferentes daquelas encontradas com a razão de 1:10 m/v, independentemente da técnica de quantificação. A maioria dessas concentrações foi maior quando se usou a razão de 1:5 m/v e alterou a classe de interpretação dos teores. Portanto, não recomenda-se o uso da razão solo:extrator de 1:5 para as extrações dos micronutrientes Cu, Fe, Mn e Zn com solução M-1 de amostras de solo.

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

BACKGROUND: Second line endocrine therapy has limited antitumour activity. Fulvestrant inhibits and downregulates the oestrogen receptor. The mitogen-activated protein kinase (MAPK) pathway is one of the major cascades involved in resistance to endocrine therapy. We assessed the efficacy and safety of fulvestrant with selumetinib, a MEK 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor (AI). PATIENTS AND METHODS: This randomised phase II trial included postmenopausal patients with endocrine-sensitive breast cancer. They were ramdomised to fulvestrant combined with selumetinib or placebo. The primary endpoint was disease control rate (DCR) in the experimental arm. ClinicalTrials.gov Indentifier: NCT01160718. RESULTS: Following the planned interim efficacy analysis, recruitment was interrupted after the inclusion of 46 patients (23 in each arm), because the selumetinib-fulvestrant arm did not reach the pre-specified DCR. DCR was 23% (95% confidence interval (CI) 8-45%) in the selumetinib arm and 50% (95% CI 27-75%) in the placebo arm. Median progression-free survival was 3.7months (95% CI 1.9-5.8) in the selumetinib arm and 5.6months (95% CI 3.4-13.6) in the placebo arm. Median time to treatment failure was 5.1 (95% CI 2.3-6.7) and 5.6 (95% CI 3.4-10.2) months, respectively. The most frequent treatment-related adverse events observed in the selumetinib-fulvestrant arm were skin disorders, fatigue, nausea/vomiting, oedema, diarrhoea, mouth disorders and muscle disorders. CONCLUSIONS: The addition of selumetinib to fulvestrant did not show improving patients' outcome and was poorly tolerated at the recommended monotherapy dose. Selumetinib may have deteriorated the efficacy of the endocrine therapy in some patients.

1.84 micron emission of Tm3+ sensitized by Yb3+ ions in monoclinic KGd(WO4)2 single crystals

By exciting at 940 nm, we have characterized the 1.84 m near infrared emission of trivalent thulium ions in Yb3+, Tm3+:KGd WO4 2 single crystals as a function of the dopant concentration and temperature, from 10 K to room temperature. An overall 3H6 Stark splitting of 470 cm−1 for the Tm3+ ions in the Yb3+, Tm3+:KGd WO4 2 was obtained. We also studied the blue emission at 476 nm Tm3+ and the near infrared emissions at 1.48 m Tm3+ and 1 m Yb3+ as a function of the dopant concentration. Experimental decay times of the 1G4, 3H4, and 3F4 Tm3+ and 2F5/2 Yb3+ excited states have been measured as a function of Yb3+ and Tm3+ ion concentrations. For the 3F4 →3H6 transition of Tm3+ ions, we used the reciprocity method to calculate the maximum emission cross section of 3.07 10−20 cm2 at 1.84 m for the polarization parallel to the Nm principal optical direction.

Integração de pAN7-1 no genoma de Magnaporthe grisea mediada por enzima de restrição

Visando explorar a mutagênese insercional em Magnaporthe grisea, foram avaliadas a transformação dos protoplastos obtidos após adequação do protocolo e a eficiência da integração de pAN7-1 no genoma do ascomiceto na presença da enzima de restrição Hind III. Os protoplastos de M. grisea I-22 foram prontamente transformados para a resistência à higromicina. Quando o vetor linearizado com Hind III foi usado para transformar o fungo na presença de Hind III, a eficiência de transformação foi 1,1 a 8,1 vezes superior ao tratamento sem a adição da enzima. No geral, a melhor concentração de Hind III foi 5 unidades/reação de transformação. Tal concentração promoveu a produção média de 332 transformantes/µg de pAN7-1/10(7) protoplastos. A presença do gene de seleção hph no genoma de 18 indivíduos resistentes à higromicina foi confirmada por PCR.

Caracterização de amostras atenuadas do vírus da Diarréia Viral Bovina (BVDV) tipos 1 e 2 para uso em vacinas

Este artigo relata a caracterização de duas amostras citopáticas do vírus da Diarréia Viral Bovina (BVDV-1: IBSP-2; BVDV-2: SV-253) submetidas à atenuação por múltiplas passagens em cultivo celular e exposição à radiação ultravioleta. As amostras foram caracterizadas in vitro (tamanho e morfologia de placas, cinética de replicação e perfil antigênico) e in vivo (atenuação e resposta sorológica em bovinos). A caracterização in vitro de populações clonadas dos vírus obtidas nas diferentes passagens em cultivo celular (0, 1, 10, 20 e 30), demonstrou que o processo de atenuação não afetou negativamente as características antigênicas e fenotípicas das amostras. Não foram observadas alterações significativas no tamanho e morfologia de placas e na cinética de replicação. A reatividade com 48 anticorpos monoclonais demonstrou que o perfil antigênico não doi alterado durante as sucessivas passagens in vitro. A inoculação intramuscular dos clones de vírus obtidos na passagem 30 (IBSP-2: 10(7,3) DICC50; SV-253: 10(6,8) DICC50) em 12 novilhas soronegativas com idade média de 15 meses, não resultou em sinais clínicos, comprovando sua atenuação. Após a inoculação, o vírus foi detectado em leucócitos da maioria dos animais inoculados (10/12) entre os dias 3 e 6 pós-inoculação (pi) e em secreções nasais de três animais (dias 4, 7 e 8pi). No entanto, não ocorreu transmissão dos vírus vacinais aos três animais soronegativos mantidos como sentinelas. Todos os animais vacinados soroconverteram aos 14 dias pós-vacinação (dpv). Títulos moderados a altos de anticorpos neutralizantes foram detectados frente a 5 isolados brasileiros do BVDV-1 (títulos de 80 a > 1280) e quatro isolados do BVDV-2 (títulos de 20 a 640). Em geral, os títulos foram de magnitude superior frente a isolados brasileiros do BVDV-1. Aos 240dpv, os animais receberam uma segunda dose dos vírus vacinais (IBSP-2: 10(7,3) DICC50; SV-253: 10(6,8) DICC50). A revacinação induziu uma resposta secundária na maioria dos animais, resultando em um aumento dos títulos de anticorpos neutralizantes principalmente frente ao BVDV-2. Esses resultados são promissores no sentido da utilização dessas amostras na formulação de vacinas atenuadas para o controle da infecção pelo BVDV no Brasil.

Valtatien 10 kehittäminen välillä Hattelmala (vt 3) – Velssi, Hämeenlinna : Aluevaraussuunnitelma

Valtatiet 10 ja 12 muodostavat valtakunnallisesti merkittävän itä–länsisuuntaisen poikittaisen päätieyhteyden Turusta Hämeenlinnan ja Lahden kautta Kouvolaan. Hämeenlinnan ja Lahden välillä valtatiet kuuluvat maan tärkeimpien pääteiden verkkoon. Valtatiet 10 ja 12 Hämeenlinnasta Lahteen kuuluvat EU:n päättämään kattavaan (TEN-T) verkkoon. Suunnitelmassa on käsitelty valtatien 10 (Turku–Hämeenlinna–Tuulos) kehittämistä Hämeenlinnan kaupunkiseudun kohdalla. Työ rajautuu lännessä valtateiden 3 ja 10 eritasoliittymän itäpuolelle (2+2-kaistaisen osuuden loppuun) ja idässä Velssiin. Tarkasteltavan alueen pituus on noin kahdeksan kilometriä. Aluevaraussuunnitelmassa on määritelty tiejakson kehittämisen tavoitetilanne ja tärkeimmät 1.vaiheen kehittämistoimenpiteet jatkosuunnittelun ja maankäytön suunnittelun pohjaksi. Aluevaraussuunnitelma toimii alueen kaavoituksen lähtöaineistona ja kaavoituksen yhteydessä on joitakin vaikutuksia tarkennettava. Suunnitelman varsinainen käsittely tapahtuu pääosin kaavoituksen tai yksittäisten kohteiden tiesuunnitelmien laatimisen yhteydessä. Valtatien 10 tavoitetilassa tie parannetaan nykyisessä maastokäytävässä Hattelmalasta Ruununmyllyyn 2+2-kaistaiseksi kaupunkipääväyläksi, jolla on vain eritasoliittymiä ja nopeusrajoitus 80 km/h lukuun ottamatta Vanajan eritasoliittymän ja Katisten–Viipurintien liittymien välistä osuutta, jossa nopeusrajoitus on vähintään 60 km/h, mutta mielellään 70 km/h. Ruununmyllystä itään tavoitetilana on jatkuva ohituskaistatie, jonka nopeusrajoitus on 100 km/h. Tielle tehdään Katuman, Katisten ja Kahiliston eritasoliittymät. Vanajan eritasoliittymään parannetaan. Viipurintien liittymä muutetaan suuntaisliittymäksi. Kahiliston ja Siirin välille jää kaksi tasoliittymää. Rinnakkaista katuverkkoa täydennetään. Myös Paasikiventien jatkeeseen on varauduttu. Jalankulun ja pyöräilyn yhteyksiä parannetaan ja tehdään melutorjuntaa. Tavoitetilanteen kustannusennuste on 49,8 miljoonaa euroa (MAKU2005; 137,0). Ensimmäisen vaiheen parantamistoimenpiteet kohdistuvat Katuman ja Katisten liittymiin sekä osuudelle Kahilisto–Velssi. Kaikissa kohteissa on esitetty vaihtoehtoisia ratkaisuja, joiden valintaan vaikuttavat maankäytön kehittyminen sekä saatava rahoitus.

Residual ß-cell function and microvascular complications in type 1 diabetic patients

To determine the influence of residual ß-cell function on retinopathy and microalbuminuria we measured basal C-peptide in 50 type 1 diabetic outpatients aged 24.96 ± 7.14 years, with a duration of diabetes of 9.1 ± 6.2 years. Forty-three patients (86%) with low C-peptide (<0.74 ng/ml) had longer duration of diabetes than 7 patients (14%) with high C-peptide (³0.74 ng/ml) (9 (2-34) vs 3 (1-10) years, P = 0.01) and a tendency to high glycated hemoglobin (HBA1) (8.8 (6-17.9) vs 7.7 (6.9-8.7)%, P = 0.08). Nine patients (18%) had microalbuminuria (two out of three overnight urine samples with an albumin excretion rate (AER) ³20 and <200 µg/min) and 13 (26%) had background retinopathy. No association was found between low C-peptide, microalbuminuria and retinopathy and no difference in basal C-peptide was observed between microalbuminuric and normoalbuminuric patients (0.4 ± 0.5 vs 0.19 ± 0.22 ng/ml, P = 0.61) and between patients with or without retinopathy (0.4 ± 0.6 vs 0.2 ± 0.3 ng/ml, P = 0.43). Multiple regression analysis showed that duration of diabetes (r = 0.30, r2 = 0.09, P = 0.031) followed by HBA1 (r = 0.41, r2 = 0.17, P = 0.01) influenced basal C-peptide, and this duration of diabetes was the only variable affecting AER (r = 0.40, r2 = 0.16, P = 0.004). In our sample of type 1 diabetic patients residual ß-cell function was not associated with microalbuminuria or retinopathy.

Anxiolytic-like effects of 4-phenyl-2-trichloromethyl-3H-1,5-benzodiazepine hydrogen sulfate in mice

The pharmacological effects of 4-phenyl-2-trichloromethyl-3H-1,5-benzodiazepine hydrogen sulfate (PTMB), a novel synthetic benzodiazepine, were examined in mice. In the elevated plus-maze test of anxiety, 0.3-1 mg/kg diazepam ip (F(3,53) = 3.78; P<0.05) and 1-10 mg/kg PTMB ip increased (F(5,98) = 3.26; P<0.01), whereas 2 mg/kg picrotoxin ip decreased (F(3,59) = 8.32; P<0.001) the proportion of time spent in the open arms, consistent with an anxiolytic action of both benzodiazepines, and an anxiogenic role for picrotoxin. In the holeboard, 1.0 mg/kg diazepam ip increased (F(3,54) = 2.78; P<0.05) and 2 mg/kg picrotoxin ip decreased (F(3,59) = 4.69; P<0.01) locomotor activity. Rotarod assessment revealed that 1 mg/kg diazepam ip and 3, 10 and 30 mg/kg PTMB ip produced significant motor incoordination compared to vehicle control (F(4,70) = 7.6; P<0.001). These data suggest that the recently synthesized PTMB compound possesses anxiolytic activity and produces motor incoordination similar to those observed with diazepam.

Sleep deprivation reduces the lymphocyte count in a non-obese mouse model of type 1 diabetes mellitus

The objective of the present study was to determine whether sleep deprivation (SD) would promote changes in lymphocyte numbers in a type 1 diabetes model (non-obese diabetic, NOD, mouse strain) and to determine whether SD would affect female and male NOD compared to Swiss mice. The number of lymphocytes in peripheral blood after 24 and 96 h of SD (by multiple platform method) or equivalent period of time in home-cage controls was examined prior to the onset of diabetes. SD for 96 h significantly reduced lymphocytes in male Swiss mice compared to control (8.6 ± 2.1 vs 4.1 ± 0.7 10³/µL; P < 0.02). In male NOD animals, 24- and 96-h SD caused a significant decrease of lymphocytes compared to control (4.4 ± 0.3 vs 1.6 ± 0.5; P < 0.001 and 4.4 ± 0.3 vs 0.9 ± 0.1 10³/µL; P < 0.00001, respectively). Both 24- and 96-h SD induced a reduction in the number of lymphocytes in female Swiss (7.5 ± 0.5 vs 4.5 ± 0.5, 4.4 ± 0.6 10³/µL; P < 0.001, respectively) and NOD mice (4 ± 0.6 vs 1.8 ± 0.2, 1.2 ± 0.4 10³/µL; P < 0.01, respectively) compared to the respective controls. Loss of sleep induced lymphopenia in peripheral blood in both genders and strains used. Since many cases of autoimmunity present reduced numbers of lymphocytes and, in this study, it was more evident in the NOD strain, our results suggest that SD should be considered a risk factor in the onset of autoimmune disorders.